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Abstract 34 
Background: Hypoxia is a common feature of many congenital heart defects (CHDs) and 35 
significantly contributes to their pathophysiology. Thus, understanding the mechanism underlying 36 
cell response to hypoxia is vital for the development of novel therapeutic strategies. Certainly, the 37 
hypoxia inducible factor (HIF) has been extensively investigated and it is now recognized as the 38 
master regulator of cell defense machinery counteracting hypoxic stress. Along this line, we 39 
recently discovered and reported a novel mechanism of HIF activation, which is mediated by 40 
sialidase NEU3. Thus, aim of this study was to test whether NEU3 played any role in the cardiac 41 
cell response to chronic hypoxia in congenital cyanotic patients. 42 
Methods: Right atrial appendage biopsies were obtained from pediatric patients with 43 
cyanotic/non-cyanotic CHDs and processed to obtain mRNA and proteins. Real-Time PCR and 44 
Western Blot were performed to analyze HIF-1α and its downstream targets expression, NEU3 45 
expression, and the NEU3 mediated effects on the EGFR signaling cascade. 46 
Results: Cyanotic patients showed increased levels of HIF-1α, NEU3, EGFR and their 47 
downstream targets, as compared to acyanotic controls. The same patients were also characterized 48 
by increased phosphorylation of the EGFR signaling cascade proteins. Moreover, we found that 49 
HIF-1α expression levels positively correlated with those recorded for NEU3 in both cyanotic and 50 
control patients. 51 
Conclusions: Sialidase NEU3 plays a central role in activating cell response to chronic hypoxia 52 
inducing the up-regulation of HIF-1α, and this represent a possible novel tool to treat several CHD 53 
pathologies. 54 
 55 
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1. Introduction 59 
Hypoxia significantly contributes to the pathophysiology of many common congenital heart defects, 60 
including the Tetralogy of Fallot (TOF) [1]. Before surgical correction, the heart, as well as the 61 
other organs and tissues of these patients, is exposed to chronic hypoxia, which is known to have 62 
lasting effects even after surgical repair [2]. Indeed, surgical repair usually consists in closing a 63 
ventricular septal defect and widening the right ventricular outflow tract to the pulmonary artery, 64 
which relives hypoxia and dramatically reduces the pressure. However, persistent pulmonary 65 
regurgitation after repair is common, and it contributes to progressive RV dilatation, often 66 
culminating in RV failure [3]. The rate at which these dysfunctions progress is variable among 67 
patients, suggesting that individual differences are crucial and should be elucidated for the 68 
development of novel therapeutic approaches [4]. Furthermore, the understanding of the biological 69 
pathways involved in RV remodeling becomes vital also for the development of new diagnostic 70 
tools for an early identification of high risk-patients, before significant RV remodeling has 71 
occurred. In particular, it is now clear that the hypoxia inducible factor-1α (HIF-1α), the master 72 
gene of cell response to hypoxia, plays a crucial role in cardioprotection [5]. In fact, when the 73 
oxygen level goes down, mammalian cells have developed an adaptive system to overcome 74 
conditions of moderate-severe hypoxia, mainly regulated by HIF-1α [6, 7], which eventually 75 
activates pro-survival signaling pathways. 76 
There is now a general agreement that HIF-mediated cell response to hypoxia is different under 77 
acute or chronic conditions, and the effects of this transcription factor can be either beneficial or 78 
detrimental. In fact, it has been shown that while an increase in the level of HIF-1α is one of the 79 
first adaptations of the human heart to acute ischemic conditions, a sustained stabilization of this 80 
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factor, typical of chronic conditions, leads to dilated cardiomyopathy, with fibrosis, myocyte loss, 81 
lipid accumulation, and other detrimental effects [8]. However, surprisingly, HIF-induced fibrosis 82 
should not be always seen as detrimental, as it has been shown that patients with low expression of 83 
HIF-1α have less fibrosis at time of intervention, but enhanced adverse ventricular remodeling after 84 
surgical repair [9]. These results support the hypothesis that an activation of HIF-1α before surgical 85 
correction of the defects is desirable, as it promotes long-term beneficial effects in the patients. 86 
However, the mechanism behind this hypothesis has yet to be fully elucidated. 87 
At this stage, it seems clear that the mechanism of HIF-1α activation is very complex and still needs 88 
further investigation. Moreover, how this crucial transcription factor affects the heart is still unclear, 89 
as it depends on many factors. Along this line, we recently discovered a novel pathway of HIF-1α 90 
activation in murine skeletal muscular myoblasts, which is different from the “canonical” inhibition 91 
of prolyl hydroxylase 2 (PHD2) [10], and it is regulated by the membrane-bound sialidase NEU3 92 
[11]. NEU3 is a glycosidase responsible for the removal of sialic acid from glycosphingolipids, and 93 
it has been shown to possess trans-activity since it can also work on the gangliosides present on the 94 
plasma membrane of adjacent cells [12-14]. These key features are likely instrumental for a crucial 95 
role played by the enzyme in many cellular processes [15] including cell proliferation and 96 
differentiation [16-18]. Specifically, we showed that sialidase NEU3 is transcriptionally activated 97 
under hypoxia in skeletal muscle cells, and that activated NEU3 triggers a signaling cascade 98 
mediated by ganglioside GM3, which activates the EGF receptor (EGFR) and its downstream anti-99 
apoptotic and pro-proliferative signaling pathways, ultimately leading to HIF-1α activation. 100 
Moreover, stable overexpression of sialidase NEU3 significantly enhances myoblasts resistance to 101 
hypoxia, whereas stable silencing of the enzyme renders cells more susceptible to apoptosis [11].  102 
These data support the working hypothesis of a physiological role played by NEU3 sialidase in 103 
protecting cells from hypoxic stress. 104 
 5 
Based on these premises, the main aim of this study was to test whether NEU3 plays a role in 105 
cardiac muscle response to chronic hypoxia in congenital heart patients, ultimately triggering HIF-106 
1α signaling cascade.  107 
 108 
 109 
2. Materials and methods 110 
2.1. Patients  111 
Pediatric patients with cyanotic and non-cyanotic congenital heart diseases, undergoing elective 112 
cardiac surgery correction with extracorporeal circulation at the Cardiac Surgery Division of San 113 
Donato Hospital, were enrolled for this study after understanding and signing an informed consent. 114 
Patients enrolled respected the inclusion and exclusion criteria of the study approved by the 115 
Hospital Ethics Committee and received an alpha-numeric code to be univocally identified. All data 116 
related to the patient disease and his cardiac surgery were recorded. 117 
 118 
2.2. Tissue biopsies 119 
Right atrial appendage biopsies were obtained from the point of atrial cannulation at the beginning 120 
of extracorporeal circulation. Tissue specimens weighted about 100 mg and were collected in cold 121 
phosphate buffer solution (PBS) at pH 7.4, kept in ice and processed within minutes after 122 
collection. 123 
 124 
2.3. mRNA isolation from cardiac tissue samples 125 
For mRNA extraction, tissue samples were retrieved from saline solution within 30 minutes, 126 
incubated with 1 ml of Trizol-LS reagent (Invitrogen, Carlsbad, CA, USA) and then homogenized 127 
using the Tissue homogenizer Lyser® (Qiagen). Each sample was processed with 2 cycles of 10 128 
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min each at 25 oscillations/sec, kept in ice for 30 min and finally centrifuged at 12000 rcf for 5 min 129 
at 4°C. After centrifugation, the supernatant of each sample was transferred in a new tube and total 130 
mRNA was extracted from Trizol-LS following the manufacture’s protocol.  131 
 132 
2.4. mRNA purification and retro-transcription into the 133 
corresponding cDNA 134 
To eliminate possible genomic DNA contaminations in the extracted mRNA, samples were 135 
processed according to the "RNA Cleanup" protocol of RNeasy Mini Kit® (QIAGEN) supplied by 136 
the company. After isolation and purification, 1 μg of RNA was reverse-transcribed to cDNA using 137 
the iScript cDNA Synthesis Kit (Bio-Rad Laboratories) according to the Manufacturer’s instruction.  138 
 139 
2.5. Gene expression analyses by Real-Time PCR 140 
For qPCR analyses, 10 ng of total RNA were used as a template with a StepOnePlus® Real-Time 141 
PCR System (Thermo Fisher Scientific). The PCR mixture included also: 0.2 µM of primers 142 
(Suppl. Table 1) and 10 µl of Power SYBR® Green Master Mix (Thermo Fisher Scientific), in a 143 
final volume of 20 µl. Amplification and qPCR data acquisition were performed using the 144 
following conditions: initial denaturation at 95°C for 2 min, followed by 40 cycles of 5 sec each at 145 
95°C, 30 sec at 57°C and 30 sec at 72°C. A final elongation step was performed at 72°C for 2 146 
minutes. Relative quantification of target genes was performed in triplicate and was calculated by 147 
the equation 2-ΔΔCt using as housekeeper gene the ribosomal protein S14, which is a component of 148 
the 40S subunit [19]. The accuracy was monitored by analysis of the PCR-product melting curve.  149 
 150 
2.6. Total protein extraction from Trizol-LS samples 151 
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Proteins from the phenol/chloroform layer obtained during the RNA extraction with Trizol-LS, 152 
were extracted by the following protocol: 1.2 mL of cold methanol were added to the 153 
phenol/chloroform layer and vortexed, then samples were left for 10 min at 30°C and, after an 154 
incubation on ice for 5 min, were centrifuged at 12,000 rcf for 10 min at 4°C to sediment the 155 
proteins. The protein pellets were washed with 1 mL of cold methanol and centrifuged again at 156 
12,000 rcf for 10 min at 4°C. After centrifugation, protein pellets were resuspended in 0.5 mL of 157 
cold methanol and sonicated for 4 cycles of 5 sec each in ice using burst sonication to generate a 158 
fine protein powder. Samples were then centrifuged for 1 min at 2,000 rcf and the methanol 159 
evaporated at room temperature. Proteins were then resuspended with 200 µL of a 0.25% 160 
Rapigest® solution in 50 mM ammonium bicarbonate and solubilized by alternate cycles of vortex 161 
and heat at 60°C. The obtained proteins were stored at -80°C until used for Western Blot 162 
experiments. 163 
 164 
2.7. Membrane and cytosolic protein separation 165 
To obtain membrane and cytosolic protein fractions, fragments of auricles were incubated with PBS 166 
containing 1% protease and phosphatase inhibitors (Sigma-Aldrich) and homogenized using the 167 
Tissue homogenizer Lyser® (Qiagen). Each sample was processed with 4-5 cycles of 10 min each 168 
at 25 oscillations/sec and the total tissue suspensions were lysed by sonication and then centrifuged 169 
at 800 rcf for 10 min to eliminate debris, unbroken cells and nuclear components. The obtained 170 
supernatants were subsequently centrifuged at 200,000 rcf at 4°C for 20 min on a TL100 171 
Ultracentrifuge (Beckman) to obtain a soluble and a particulate fraction. The particulate fraction 172 
contains the plasmatic membranes, the lysosomal membranes, and the endoplasmic reticulum, 173 
while the supernatant contains the cytosol. Both fractions were used for NEU3 expression analyses 174 
by Western Blot. Relative NEU3 protein expression levels were calculated normalizing data using 175 
Na+/K+ ATPase as housekeeper for the membranes and EEA1 as housekeeper for the cytosol. 176 
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2.8. Protein expression analyses by Western Blot 178 
Protein concentrations were measured by the Pierce™ BCA Protein Assay Kit (Thermo Fisher 179 
Scientific), following the Manufacturer’s protocol. 30 µg of proteins were denatured by boiling for 180 
5 min in sample buffer (6.5 mM Tris-HCl, pH 6.8, 2% SDS (w/v), 10% glycerol (v/v), 5% 2-181 
mercaptoethanol (w/v), 0.01% bromophenol blue (w/v)) and separated on a 10% polyacrylamide 182 
gel in denaturing conditions. Proteins were subsequently transferred into nitrocellulose membranes 183 
by electroblotting using 100 Volt for 2 hours. Then, the membranes were incubated overnight in 184 
Tris-buffered saline (TBS: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl), 0.1% (v/v) Tween 20 (TBS-185 
Tween) containing 5% (w/v) dried milk or 5% (w/v) bovine serum albumin (BSA; Sigma) for the 186 
blocking buffer. Blots were incubated with a primary antibody (Suppl. Table 2) in the appropriate 187 
blocking solution for three hours at room temperature. Membranes were then washed four times for 188 
10 min with TBS-Tween and then incubated with the appropriate secondary antibody horseradish 189 
peroxidase (HRP) conjugated for 1 hour at room temperature. After four washes in TBS-Tween, the 190 
protein bands were detected using an ECL detection kit (Thermo Fisher Scientific) as described by 191 
the Manufacturer. Relative protein expression levels were calculated normalizing data on Calnexin 192 
(Clx), Na+/K+ ATPase (membranes fraction) and EEA1 (cytosol fraction) expression, which were 193 
used as internal controls. 194 
 195 
2.9. Statistical analysis 196 
Data were expressed as a percentage for nominal variables and mean with standard deviations for 197 
continuous variables using GraphPad Prism 6 (GraphPad Software Inc, California, USA). Statistical 198 
differences were determined by Unpaired T-test (* p<0.05; ** p<0.01; *** p<0.001). 199 
The correlation analysis was tested by Pearson method on Delta Ct values of gene expression of 200 
cyanotic and acyanotic patients using GraphPad Prism 6 (GraphPad Software Inc, California, USA). 201 
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 202 
 203 
 204 
 205 
 206 
3. Results 207 
3.1. Characterization of patients 208 
Patients included in the study were divided in two groups based on the presence of cyanotic or 209 
acyanotic congenital heart defects. The number of patients included in the acyanotic and cyanotic 210 
groups was 17 and 18, respectively. Each group was composed by patients with different congenital 211 
heart malformations, as shown in Table 1, to increase sample heterogeneity. Different clinical 212 
parameters were measured in both cyanotic or acyanotic groups as shown in Table 2. BMI, 213 
Creatinine, electrolytes (Na+; K+), PT, PTT and platelets count did not show any statistically 214 
significant differences between the two populations. However, acyanotic and cyanotic patients were 215 
statistically different for these clinical parameters: (a) SpO2: the level of oxygen saturation of 216 
cyanotic patients was approximately 72.5% (SD: 15.38%) as compared to 98.9% (SD: 1.23%) for 217 
control acyanotic patients;  (b) glycaemia: the average levels of glycaemia measured in cyanotic 218 
and acyanotic patients were 84.78 mg/dl (SD: 19.91 mg/dl) and 110.31 mg/dl (SD: 10.68 mg/dl), 219 
respectively; (c) hemoglobin: the average value of hemoglobin in patients with cyanotic congenital 220 
heart defects was 14.03 g/dl (SD: 3.05 g/dl) as compared to 11.98 g/dl (SD: 0.76 g/dl) of acyanotic 221 
patients. 222 
 223 
3.2. HIF-1α activation analysis in cyanotic patients  224 
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Specimens of right auricle were isolated from patients with either cyanotic or acyanotic congenital 225 
heart diseases (hereafter simply cyanotic and controls), and then they were processed for mRNA 226 
and protein extraction, as described in Materials and Methods. Analysis of HIF-1α expression by 227 
Real-Time PCR showed mRNA levels about 1.3 folds higher in cyanotic patients as compared to 228 
controls (Fig. 1A). HIF-1α protein expression by Western Blot was on average 3 folds higher in 229 
cyanotic patients than in controls (Fig. 1B). Moreover, the expression of VEGF, an important 230 
transcriptional target of HIF-1α and a key regulator in the formation of new blood vessels, was 1.2 231 
folds higher in cyanotic patients as compared to controls by Real-Time PCR (Fig. 1C). Western 232 
Blot analysis of the VEGF protein expression showed a 3 fold increase in cyanotic patients as 233 
compared to control patients (Fig. 1D). 234 
To further support the activation of the HIF-1α pathway in cyanotic congenital patients, the 235 
expression of several HIF-1α target genes involved in glucose metabolism was analyzed by Real-236 
Time PCR and Western Blot. In particular, the ubiquitous glucose transporter 1 (GLUT1) 237 
expression was 3.1 folds higher in cyanotic patients as compared to controls (Fig. 1G). 238 
Furthermore, the shift from the oxidative to the glycolytic metabolism was confirmed by the 239 
upregulation of ALDOA and GAPDH, that resulted 1.6 and 3.2 folds higher in cyanotic patients 240 
than in controls by Real-Time PCR and Western Blot analyses, respectively (Figs 1E and 1H). 241 
Moreover, the pyruvate dehydrogenase kinase 1 (PDK1), the enzyme responsible for the 242 
inactivation of the pyruvate dehydrogenase complex, was found 1.4 fold higher in cyanotic patients 243 
as compared to controls (Fig. 1F). The expression of PHD2 was analyzed by Real-Time PCR and 244 
Western Blot in cyanotic and control samples. Although no significant differences were observed in 245 
PHD2 mRNA expression levels, PHD2 protein expression was found to be 2.5 folds higher in 246 
cyanotic patients than in acyanotic controls, using as internal control the chaperone protein 247 
Calnexin (Figs 2A and 2B).  248 
 249 
3.3. NEU3 activation in cyanotic patients 250 
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To test whether chronic hypoxia affected sialidase NEU3 levels, its expression was tested by Real-251 
Time PCR. Results showed that NEU3 mRNA levels were 1.7 folds higher in cyanotic patients as 252 
compared to controls (Fig. 3A). Moreover, the expression of SP1/SP3, transcription factors, which 253 
are known to be activated under hypoxia and to bind the NEU3 promoter region, both showed an 254 
increase of about 1.3 folds in cyanotic patients as compared to controls (Figs 3B and 3C). As the 255 
active form of the sialidase NEU3 has been recently shown to be present at the level of plasma 256 
membranes [20], the separation of cytosol and membranes protein fractions was performed on 257 
auricle samples from cyanotic and acyanotic patients. Analysis of NEU3 expression by Western 258 
Blot revealed a 1.7 fold increase of NEU3 protein level in the membranes of cyanotic samples, as 259 
compared to controls, whereas the cytosol fractions did not show any significant differences, as 260 
expected (Figs 3D and 3E). 261 
 262 
3.4. Analysis of EGFR signaling pathway in cyanotic patients  263 
The effects of chronic hypoxia on the EGFR signaling cascade were tested by evaluating its 264 
expression by Western Blot, as well as that of key proteins of the pathway in their inactive and/or 265 
active phosphorylated forms. Results revealed an increase of EGFR protein expression and of its 266 
phosphorylated active form, which were 6.3 and 4.2 folds higher, respectively, in cyanotic patients 267 
as compared to controls (Fig. 4A). Moreover, downstream targets of the EGFR-signaling cascade 268 
were also up-regulated in cyanotic patients. In particular, the expression of p42/p44 MAPK, AKT 269 
and p70S6K resulted 8, 2.5 and 2.2 folds higher, respectively, in cyanotic patients as compared to 270 
acyanotic controls. Similarly, the phosphorylated active forms of the same kinases were also 271 
significantly up-regulated in cyanotic patients, (Figs 4B, 4C and 4D).  272 
 273 
3.5. HIF-1α and sialidase NEU3 correlation  274 
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To test whether NEU3 activation under chronic hypoxia leads to an activation of HIF-1α through 275 
the EGFR signaling cascade, we analyzed the correlation between the mRNA expression levels of 276 
NEU3 and HIF-1α in acyanotic and cyanotic patients. Results showed that there was a statistically 277 
significant positive correlation between NEU3 mRNA expression level and that of HIF-1α in 278 
acyanotic patients, as we expected from our previous results [11], with a Pearson's r coefficient of 279 
0.6923 and a p-value of 0.0182. Moreover, a statistically positive correlation was found also 280 
between NEU3 and HIF-1α in cyanotic patients, with a Pearson's r coefficient of 0.7038, and a p-281 
value of 0.0231 (Fig. 5). 282 
 283 
4. Discussion 284 
Herein we reported a novel mechanism of activation of HIF-1α in the heart of congenital cyanotic 285 
patients suffering of chronic hypoxic conditions, which is mediated by sialidase NEU3 (Fig. 6). 286 
While HIF-1α is constitutively expressed and is normally regulated by proteolysis in the ubiquitin-287 
proteasome pathway (upon its oxygen-dependent hydroxylation by the prolyl hydroxylases, PHDs, 288 
as described in the introduction), in this study we corroborate our previous findings in mouse 289 
skeletal muscle, where we first described that HIF-1α is up-regulated at a protein level by sialidase 290 
NEU3 via a signaling cascade involving EGFR [11]. For this purpose, we analyzed heart biopsies, 291 
from the right atrial appendage of either cyanotic or acyanotic patients undergoing surgeries for 292 
congenital heart diseases. We found that HIF-1α expression was significantly higher in cyanotic 293 
patients as compared to acyanotic controls. Moreover, HIF-1α downstream targets, including VEGF 294 
and several key genes involved in the glycolytic pathway, were also up-regulated in cyanotic 295 
patients, as already reported by Quing et al [21]. Moreover, we also found that sialidase NEU3 was 296 
up-regulated in the same cyanotic patients, in terms of mRNA and of protein levels on the 297 
membranes, as we expected from our previous mechanistic study [20]. As we anticipated, NEU3 298 
expression positively correlates with HIF-1α expression levels in both cyanotic and control patients, 299 
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supporting the hypothesis of a crucial role played by the enzyme in activating HIF-1α under 300 
hypoxia. Moreover, we found that SP1 and SP3, the two belonging to the Sp/KLF family of 301 
transcription factors and known to bind to the NEU3 promoter region, were both up-regulated in 302 
cyanotic patients, supporting the mechanism of activation of NEU3 under hypoxia that we 303 
previously reported [11]. Then, we investigated the mechanism of NEU3-mediated HIF-1α 304 
activation. Similarly to what we reported in skeletal muscle [11], we found an increase of EGFR 305 
protein expression and of its phosphorylated active form in cyanotic patients, as well as its 306 
downstream targets ERK, AKT and p70S6K, also in their phosphorylated active forms. The direct 307 
involvement of the EGFR/AKT/p70S6K pathway in the increased transcriptional and translational 308 
expression of HIF-1α was already described in smooth muscle cells and cancer. In particular, the 309 
activation of AKT is able to induce the mRNA expression of HIF-1α through the transcription 310 
factor NF-kB in pulmonary artery smooth muscle cells [22]. Moreover, it has been recently 311 
demonstrated in ovarian cancer that the activation of AKT/ERK leads to the phosphorylation and 312 
consequently to the activation of the ribosomal protein S6 kinase (p70S6K), which enhances HIF-313 
1α mRNA translation resulting in HIF-1α accumulation [23, 24]. Overall, all these evidences 314 
support the hypothesis of a direct involvement of sialidase NEU3 in regulating HIF-1α levels under 315 
chronic hypoxia conditions in congenital heart patients. Thus, triggering HIF-1α through the 316 
activation of NEU3, or mimicking the sialidase effects by chemical inhibition of GM3 synthesis (as 317 
we previously reported [25]), could be a novel tool to increase the physiological cell response to 318 
chronic hypoxic stress. Moreover, increasing the expression levels of active proteins of pro-survival 319 
pathways may represent a fundamental step to make cardiac cells and tissue more resistant to 320 
reoxygenation injuries, thus possibly enhancing cyanotic cardiac patients’ long-term outcome. 321 
While sustained HIF-1α activation may lead to cardiac fibrosis, as stated before, this should not be 322 
viewed as detrimental, given that the process could be reversible and may represent a temporary 323 
protective phenomenon during adverse conditions such as hypoxia. In fact, it has been shown that 324 
HIF-1α signaling has cardioprotective effects through reversible fibroblasts transformation of 325 
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stressed cells during chronic hypoxia in infancy, which results in better long-term myocardial 326 
adaptation to hemodynamic load [9]. In particular, this study has shown that patients with more 327 
HIF-1α-functioning alleles, i.e. more hypoxic response and RV fibrosis at time of TOF repair, had 328 
less progression of pulmonary insufficiency, less progression of RV dilation and dysfunction, and 329 
greater freedom from RV intervention and repair.  330 
 331 
4.1. Conclusions 332 
Our results further support that a better comprehension of the molecular mechanisms that affect 333 
cyanotic CHDs represents a mandatory step for the creation of personalized and more specific 334 
therapeutic approaches, with the possibility to ameliorate the short- and long-term outcomes of 335 
these patients. In this direction, the discovery that the modulation of sialidase NEU3 is crucial in 336 
HIF-1α activation provides a possible novel target for the development of more efficient therapeutic 337 
strategies for CHDs patients. 338 
 339 
4.2. Study limitations 340 
All the experiments were performed on right atrial tissue samples, which were the only heart 341 
specimens discarded during these interventions. However, it is known that is the ventricle, not the 342 
atrium, which is mostly sensitive to alterations and remodeling processes in response to chronic 343 
hypoxic conditions. As a consequence, we cannot exclude that our results, obtained using right 344 
auricle samples, do not precisely reflect what is happening at the level of the right ventricle. 345 
Anyhow, many studies have been conducted on NEU3 in other tissues, including tumors [26], and 346 
the results strongly support a general role played by sialidase NEU3 in regulating cellular responses 347 
to stress conditions, in particular activating pro-survival pathways, opposing cell death and 348 
increasing resistance to hypoxia [11, 16, 27]. Thus, based on these results, it is plausible to 349 
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speculate that the effects observed in the right atrium of cyanotic patients, which are analogous to 350 
those previously observed in other tissues, might be active also in right ventricle. 351 
 352 
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Table 1. Acyanotic and Cyanotic patients group composition in terms of different congenital 357 
heart malformations. 358 
Acyanotic Congenital Heart Defects Number 
Atrial Septal Defect (ASD) 7 
Ventricular Septal Defect (VSD) 5 
VSD (Ventricular Septal Defect) + ASD (Atrial Septal Defect) 1 
Aortic Valve Stenosis 1 
Partial Atrioventricular Canal Defect 1 
Truncus Arteriosus Type 2 1 
Tetralogy of Fallot (TOF) 1 
Total number of patients 17 
     
Cyanotic Congenital Heart Defects Number 
Tetralogy of Fallot (TOF) 8 
Double Outlet Right Ventricle (DORV) 3 
Transposition of the Great Arteries (TGA) 1 
TGA + DORV 1 
Complete Atrioventricular Canal Defect + DORV 3 
Truncus Arteriosus Type 1 1 
 16 
Pulmonary Atresia + VSD 1 
Total number of patients 18 
 359 
 360 
 361 
 362 
 363 
 364 
Table 2. Clinical characterization of acyanotic and cyanotic patients. 365 
 
Acyanotic patients Cyanotic patients 
 
Parameters Average Average p-value 
Age (months) 41.17 ± 23.8 19.32 ± 27.15 0.0165; * 
Body Mass index (BMI) (kg/m2) 16 ± 2.5 16.35 ± 1.76 0.5321; ns 
SpO2 (%) 98.94 ± 1.23 72.5 ± 15.38 < 0.0001; **** 
Glycemia (mg/dl) 110.31 ± 10.68 84.78 ± 19.91 < 0.0001; **** 
Creatinine (mg/dl) 0.37 ± 0.09 0.34 ± 0.17 0.5223; ns 
Na+ (mEq/L) 138.94 ± 1.44 138.22 ± 2.88 0.3608; ns 
K+ (mEq/L) 4.65 ± 0.6 4.79 ± 0.65 0.5132; ns 
Prothrombin Time (PT) (%) 96.125 ± 13.6 92.5 ± 11.44 0.3986; ns 
Partial Thromboplastin Time (PTT) (sec) 30.16 ± 2.65 30.89 ± 5.48 0.6226; ns 
Hemoglobin (Hb) (g/dl) 11.98 ± 0.76 14.03 ± 3.05 0.0111; * 
Platelets (x 1000/µl) 285.31 ± 109.23 302.81 ± 114.69 0.6473; ns 
 366 
 367 
 368 
 369 
 370 
 17 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
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Figures Legend 473 
 474 
Fig. 1. HIF-1α activation in congenital cyanotic patients. 475 
HIF-1α expression was analyzed by Real-Time PCR (A) and Western Blot (B). The activation of 476 
HIF-1α pathway was analyzed measuring the expression of several HIF-1α target genes by Real-477 
Time PCR as VEGF (C), ALDOA (E), PDK1 (F), GLUT1 (G) and by Western Blot as VEGF (D) 478 
and GAPDH (H). Real-Time PCR data of cyanotic patients are expressed as fold changes as 479 
compared to controls. Ribosomal protein S14 mRNA expression has been used as internal control 480 
for Real-Time PCR experiments. Western Blot data were measured by a densitometric analysis of 481 
the protein bands and expressed as arbitrary units. Chaperone protein Calnexin (Clx) expression has 482 
been used as internal control for Western Blot experiments. *p<0.05; **p<0.01; ***p<0.001. 483 
 484 
Fig. 2. PHD2 expression in congenital cyanotic patients. 485 
PHD2 mRNA expression was analyzed by Real-Time PCR and the results expressed as fold 486 
changes as compared to the control group. Ribosomal protein S14 mRNA expression has been used 487 
as internal control for Real-Time PCR experiments (A).  488 
PHD2 protein expression was analyzed by Western Blot and the results expressed as arbitrary units 489 
based on the densitometric analysis of the bands. Chaperone protein Calnexin (Clx) expression has 490 
been used as internal control for Western Blot experiments (B). *p<0.05. 491 
 492 
Fig. 3. NEU3 activation in congenital cyanotic patients. 493 
The mRNA expression of the sialidase NEU3 (A) and of the transcription factors SP1/SP3 (B-C) 494 
was analyzed by Real-Time PCR. Data of cyanotic patients are expressed as fold change as 495 
compared to controls. Ribosomal protein S14 mRNA expression has been used as internal control 496 
for Real-Time PCR experiments.  497 
NEU3 protein expression in plasma membranes (D) and cytosol (E) fractions was measured by 498 
Western Blot. The two subcellular fractions were characterized using the Na+/K+ ATPase as plasma 499 
membranes marker and EEA1 as cytosol marker. Na+/K+ ATPase and EEA1 protein expression has 500 
been used as internal control for membranes and cytosol fractions respectively. Results are 501 
expressed in arbitrary unit. *p<0.05; **p<0.01. 502 
 503 
Fig. 4. EGFR signaling pathway activation in congenital cyanotic patients. 504 
 20 
EGFR signaling pathway activation was analyzed by Western Blot. Total proteins from cyanotic 505 
and acyanotic patients were extracted and analyzed with anti-EGFR and anti-phospho-EGFR 506 
antibodies (A); anti-ERK and anti-phospho-ERK antibodies (B); anti-AKT and anti-phospho-AKT 507 
antibodies (C); anti-p70S6K and anti-phospho-p70S6K antibodies (D). Changes in protein content 508 
were quantified by densitometry and data are reported in arbitrary units. Chaperone protein 509 
Calnexin expression has been used as internal control for Western Blot experiments. *p<0.05; 510 
**p<0.01. 511 
 512 
Fig. 5. HIF-α and NEU3 correlation. 513 
The correlation between HIF-1α and sialidase NEU3 was analyzed by comparing mRNA 514 
expression levels of both protein in cyanotic and acyanotic patients. The statistical significance of 515 
the correlation was evaluated using the Pearson's r coefficient and the p-value. *p<0.05. 516 
 517 
Fig. 6. Representation of a novel HIF-1α mechanism of activation in congenital cyanotic 518 
patients mediated by NEU3. 519 
Pictures shows a schematic representation of: (A) HIF-1α degradation by proteasome in normoxic 520 
conditions; (B) HIF-1α stabilization in hypoxic conditions mediated by the inhibition of PHD2 521 
activity; (C) HIF-1α up-regulation in hypoxic conditions by the sialidase NEU3 mediated activation 522 
of the EGFR pathway. 523 
